Closing the gap between clinical and preclinical osteoarthritis research via novel biomechanics
- Thursday, April 12, 2018 from 2:00pm to 3:00pm
- Strand Union Building, Procrastinator Theater - view map
This presentation is free and open to the public.
Osteoarthritis (OA) is a non-life-threatening, but incurable, disease that ultimately results in chronic pain and disability. However, OA pain and disability is a complex phenomenon, as the severity of joint degeneration in OA patients does not necessarily correlate to the severity of symptoms. Moreover, animal models of acute joint pain may not fully replicate chronic pain mechanisms in OA. Unfortunately, the current reality for OA drug development is that safety and efficacy will need to be tested in a preclinical model prior to clinical testing. Thus, the lack of unifying relationships between OA pathogenesis and symptoms remains a significant obstacle to the development and translation of OA therapies. To improve the translation and development of OA therapeutics, our ability to investigate preclinical OA models must become more relevant to OA treatment in the clinic. This challenge is the central motivator for my research program, where my laboratory is developing engineering technologies to improve the preclinical-to-clinical translation of emerging OA diagnostics and therapeutics, including behavioral assays of symptomology in rodent preclinical models and magnetic nanoparticle technologies to assess joint-level molecular changes. These technologies can impact the preclinical evaluation of OA interventions, the development of novel diagnostics and disease modifying drugs, and the creation of new biological therapies for OA.